Supplementary Tables – Indirect comparison of pembrolizumab monotherapy versus nivolumab+ipilimumab in first-line metastatic lung cancer
收藏Mendeley Data2024-06-25 更新2024-06-27 收录
下载链接：
https://future-science-group.figshare.com/articles/dataset/Supplementary_Tables_Indirect_comparison_of_pembrolizumab_monotherapy_versus_nivolumab_ipilimumab_in_first-line_metastatic_lung_cancer/19030124/1
下载链接
链接失效反馈官方服务：
资源简介：
Table S1 Base case scenario of overall survival and progression-free survival in patients with PD-L1 TPS≥1% before matching Table S2 Landmark analysis of overall survival and progression-free survival for chemotherapy arms from KN024/KN042 and CheckMate 227 Part 1a in patients with PD-L1 TPS≥1% before and after matching Table S3 Pembrolizumab versus nivolumab+ipilimumab for overall survival and progression-free survival in patients with PD-L1 TPS≥1%, TPS≥50% and TPS 1–49%
创建时间：
2023-06-28
